PT1425272E - Isómeros óticos de um metabolito de iloperidona - Google Patents

Isómeros óticos de um metabolito de iloperidona Download PDF

Info

Publication number
PT1425272E
PT1425272E PT02767454T PT02767454T PT1425272E PT 1425272 E PT1425272 E PT 1425272E PT 02767454 T PT02767454 T PT 02767454T PT 02767454 T PT02767454 T PT 02767454T PT 1425272 E PT1425272 E PT 1425272E
Authority
PT
Portugal
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
PT02767454T
Other languages
English (en)
Inventor
Hans O Kalkman
Dominique Grimler
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1425272E publication Critical patent/PT1425272E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT02767454T 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona PT1425272E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
PT1425272E true PT1425272E (pt) 2011-10-19

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02767454T PT1425272E (pt) 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona
PT100099159T PT2305656E (pt) 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT100099159T PT2305656E (pt) 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona

Country Status (10)

Country Link
US (4) US20050020632A1 (pt)
EP (2) EP1425272B1 (pt)
JP (6) JP2005504783A (pt)
AT (1) ATE518845T1 (pt)
CY (2) CY1112039T1 (pt)
DK (2) DK2305656T3 (pt)
ES (2) ES2370634T3 (pt)
HK (2) HK1066536A1 (pt)
PT (2) PT1425272E (pt)
WO (1) WO2003020707A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
WO2006039663A2 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
KR20090029200A (ko) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
ES2542967T3 (es) 2007-03-29 2015-08-13 Vanda Pharmaceuticals Inc. Método de predecir una predisposición a la prolongación de QT
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
WO2008144599A2 (en) 2007-05-18 2008-11-27 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
JP5729808B2 (ja) * 2007-12-13 2015-06-03 ヴァンダ ファーマシューティカルズ インコーポレイテッド αアドレナリン受容体介在状態を治療する方法及び組成物
ES2483366T3 (es) 2007-12-13 2014-08-06 Vanda Pharmaceuticals Inc. Método y composición para el tratamiento de una afección mediada por el receptor de serotonina
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
CA2757646C (en) 2009-04-06 2020-03-10 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP2417267B1 (en) 2009-04-06 2016-08-17 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
EP2825167B1 (en) * 2012-03-14 2018-05-09 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
BR112017017608A2 (pt) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH ARYLHERETOARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONINERGIC RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASE
AU2020225477A1 (en) * 2019-02-21 2021-09-09 Obi Pharma Inc. Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
CA2296104A1 (en) * 1997-07-03 1999-01-14 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

Also Published As

Publication number Publication date
US20130296366A1 (en) 2013-11-07
JP2010100633A (ja) 2010-05-06
EP2305656B1 (en) 2012-10-24
US8314129B2 (en) 2012-11-20
JP2015214577A (ja) 2015-12-03
EP1425272A1 (en) 2004-06-09
ATE518845T1 (de) 2011-08-15
CY1112039T1 (el) 2015-11-04
HK1066536A1 (en) 2005-03-24
JP2013227335A (ja) 2013-11-07
DK1425272T3 (da) 2011-11-21
DK2305656T3 (da) 2013-02-11
ES2370634T3 (es) 2011-12-21
JP2013116905A (ja) 2013-06-13
ES2398434T8 (es) 2017-10-09
US20050020632A1 (en) 2005-01-27
JP2015227368A (ja) 2015-12-17
EP1425272B1 (en) 2011-08-03
ES2398434T3 (es) 2013-03-19
PT2305656E (pt) 2013-01-10
US7977356B2 (en) 2011-07-12
JP2005504783A (ja) 2005-02-17
EP2305656A1 (en) 2011-04-06
WO2003020707A1 (en) 2003-03-13
HK1156309A1 (en) 2012-09-07
US20090176739A1 (en) 2009-07-09
US20110201646A1 (en) 2011-08-18
CY1113550T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
HK1156309A1 (en) Optical isomers of an iloperidone metabolite
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
NO2015002I2 (no) Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
NO20071193L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
PL1651040T3 (pl) Grzybobójcze trójskładnikowe kompozycje substancji czynnych
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
JP2005504783A5 (pt)
NO20033732D0 (no) N-substituerte nonaryl-heterosykliske NMDA/NR2B-antagonister
NO20062370L (no) Amidderivater
NO20073366L (no) 1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
JP2010519243A5 (pt)
NZ594765A (en) Anthelmintic agents and their use
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
HK1070363A1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
PL1848691T3 (pl) Sposób otrzymywania pochodnych indolu
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
DE50005937D1 (de) 3-(4,5-dihydroisoxazol-5-yl)benzoylpyrazole
PL353977A1 (en) Method of obtaining 4-[1-hydroxy-4-[4-(hydroxydiphenyldimethyl)-1-piperidinylbutyl]-alpha,alpha-dimethylbenzene acetic acid
DE60013751D1 (de) Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten
SE0102809D0 (sv) Novel compounds
HN2005000205A (es) Compuestos terapeuticos